Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Truist Financial Analyst Says
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Truist Financial Analyst Says MarketBeat
Covered in this story
Analyst targets on Amgen
- Cantor Fitzgerald: $403 → $400 by Oct 2027 · Neutral via Investing.com
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from MarketBeat's public RSS feed. The full reporting belongs to MarketBeat — please read it on their site.